SecurityAVGR / Avinger, Inc. (053734109)
IndustrySurgical and Medical Instruments and Apparatus
Institutional Owners9
Institutional Shares952,253 - 8.24%
Common Shares Outstanding11,552,052 shares (as of 2018-06-30)
Institutional Value$ 5,362,000 USD

Institutional Stock Ownership and Shareholders

AVGR / Avinger, Inc. Institutional Ownership

Avinger, Inc. (NASDAQ:AVGR) has 9 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 952,253 shares. Largest shareholders include BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, R&F Capital Advisors LP, Numeric Investors Llc, Ameriprise Financial Inc, BlackRock Advisors LLC, Integrated Wealth Counsel, Llc, and Meeder Asset Management Inc.
Avinger, Inc. (NASDAQ:AVGR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-08-07 13F-HR ROBERTSON STEPHENS ADVISORS LLC 33,820 0 -100.00 64 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 85,851 85,851 0.00 410 318 -22.44
2018-08-14 13F-HR AMERIPRISE FINANCIAL INC 12,025 20
2017-08-14 13F-HR NUMERIC INVESTORS LLC 14,600 14,600 0.00 28 7 -75.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 160,907 213,922 32.95 768 792 3.13
2017-02-06 13F-HR INTEGRATED WEALTH COUNSEL, LLC 4,000 4,000 0.00 19 15 -21.05
2018-02-14 13F-HR NUMERIC INVESTORS LLC 14,600 0 -100.00 6 0 -100.00
2018-07-24 13F-HR MEEDER ASSET MANAGEMENT INC 1,046 1,179 12.72 1 1,969 196,800.00
2017-02-10 13F-HR BlackRock Advisors LLC 7,088 7,534 6.29 34 28 -17.65
2017-02-10 13F-HR BlackRock Fund Advisors 496,183 582,483 17.39 2,367 2,155 -8.96
2017-05-15 13F-HR R&F Capital Advisors LP 30,659 58
AVGR : Avinger Stock Analysis and Research Report

2017-11-10 - Asif

Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease, or PAD. Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system available in this market. The company manufacture and sell a suite of products in the United States and select international markets. The company's current products include its Lightbox imaging console, as well as its Wildcat, Kittycat 2, and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion, or CTO, and Pantheris, its image-guided atherectomy ...

Related News Stories

Your Daily Pharma Scoop: Viking's Data Readout, Alpelisib Succeeds, Shire Receives Approval

2018-08-25 seekingalpha
Discussion: Share price of Viking Therapeutics (VKTX) has moved up 7% on average volume ahead of mid-stage data readout of its candidate VK2809. The anticipated trial data is indicated in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD). The candidate has a similar mechanism to Madrigal’s (NASDAQ:MDGL) MGL-3196. Viking had a June breakout connected to Madrigal’s successful mid-stage trial results. (16-4)

Avinger's (AVGR) CEO Jeff Soinski on Q2 2018 Results - Earnings Call Transcript

2018-08-14 seekingalpha
Greetings. And welcome to the Avinger’s Second Quarter 2018 Earnings Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] (1-0)

Rounds Report: Crispr Rallied While The FDA Approved Lumivascular

2018-05-25 seekingalpha
The bioscience market logged further gains for the second consecutive day this week. Many equities under our coverage continued to move northbound. (75-1)

Avinger's (AVGR) CEO Jeff Soinski on Q1 2018 Results - Earnings Call Transcript

2018-05-14 seekingalpha
Greetings and welcome to Avinger’s 2018 First Quarter Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] I’ll remind you that this conference is being recorded. (62-5)

CUSIP: 053734109